SCHEMBL1925467

SCHEMBL1925467

CCOC(=O)C=Cc1c(Cl)cccc1Cl

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.57
MAPT P10636 2/20 0.57
CA12 O43570 1/20 0.53
CA1 P00915 1/20 0.53
CA2 P00918 1/20 0.53
CA7 P43166 1/20 0.53
CA9 Q16790 1/20 0.53
CA14 Q9ULX7 1/20 0.53
HPGD P15428 2/20 0.51
GLA P06280 1/20 0.51
LMNA P02545 1/20 0.51
KMT2A Q03164 3/20 0.50
TTR P02766 1/20 0.49
DPP4 P27487 1/20 0.49
POLB P06746 1/20 0.49
TDP1 Q9NUW8 1/20 0.48
CYP3A4 P08684 2/20 0.47
ALDH1A1 P00352 1/20 0.45
MAOB P27338 1/20 0.44
CYP1A2 P05177 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1925465 1.00 L3MBTL1 (0.57) L3MBTL1MAPTCA12CA1CA2
SCHEMBL29960359 0.91 MAPT (0.52) L3MBTL1MAPTCA12CA1CA2
SCHEMBL2200893 0.90 KMT2A (0.55) L3MBTL1MAPTCA12CA1CA2
SCHEMBL15826997 0.90 KMT2A (0.55) L3MBTL1MAPTCA12CA1CA2
SCHEMBL18069260 0.90 L3MBTL1 (0.51) L3MBTL1MAPTCA12CA1CA2
SCHEMBL2200892 0.90 KMT2A (0.55) L3MBTL1MAPTCA12CA1CA2
SCHEMBL11352868 0.86 L3MBTL1 (0.48) L3MBTL1MAPTCA12CA1CA2
SCHEMBL16265449 0.83 MAPT (0.50) L3MBTL1MAPTCA12CA1CA2
SCHEMBL16265450 0.83 MAPT (0.50) L3MBTL1MAPTCA12CA1CA2
SCHEMBL1891555 0.83 MAPT (0.56) L3MBTL1MAPTCA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10723998-B2 Application of ethyl p-methoxycinnamate and derivatives thereof in maintaining self-renewal and pluripotency of stem cells NORTHEAST NORMAL UNIVERSITY (CN) 2020-07-28 US claimed
US-20180195039-A1 APPLICATION OF ETHYL P-METHOXYCINNAMATE AND DERIVATIVES THEREOF IN MAINTAINING SELF-RENEWAL AND PLURIPOTENCY OF STEM CELLS NORTHEAST NORMAL UNIVERSITY (CN) 2018-07-12 US claimed
EP-0095640-B1 ALKYLENE-BRIDGED GUANIDINO-THIAZOLE DERIVATIVES, METHOD FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS BAYER AG (DE) 1986-01-29 EP claimed
CN-115804766-A Application of compound in preparation of medicine for improving insulin resistance 东北师范大学 2023-03-17 CN disclosed
US-10723998-B2 Application of ethyl p-methoxycinnamate and derivatives thereof in maintaining self-renewal and pluripotency of stem cells NORTHEAST NORMAL UNIVERSITY (CN) 2020-07-28 US disclosed
US-20180195039-A1 APPLICATION OF ETHYL P-METHOXYCINNAMATE AND DERIVATIVES THEREOF IN MAINTAINING SELF-RENEWAL AND PLURIPOTENCY OF STEM CELLS NORTHEAST NORMAL UNIVERSITY (CN) 2018-07-12 US disclosed
EP-1431293-B1 WATER-SOLUBLE PHENYLPYRIDAZINE DERIVATIVES AND DRUGS CONTAINING THE SAME KOWA CO (JP) 2011-06-08 EP disclosed
US-7211577-B2 Water-soluble phenylpyridazine derivative and medicine containing the same KOWA CO., LTD. (JP) 2007-05-01 US disclosed
US-20060142292-A1 4-(4-tert-butoxycarbonyl-1-piperazinyl)methyl-6-(3-fluoro-4-methylphenyl)-2-isobutyl-2H-pyridazin-3-one;inhibiting interleukin-1 beta, high water solubility and oral absorbability; treating immune system diseases, inflammatory diseases, and ischemic diseases KOWA CO., LTD. (JP) 2006-06-29 US disclosed
EP-1604984-A1 WATER-SOLUBLE PHENYLPYRIDAZINE DERIVATIVE AND MEDICINE CONTAINING THE SAME Kowa Co., Ltd. (JP) 2005-12-14 EP disclosed
US-6861428-B2 Water-soluble phenylpyridazine compounds and compositions containing the same KOWA CO., LTD. (JP) 2005-03-01 US disclosed
EP-1431293-A1 WATER-SOLUBLE PHENYLPYRIDAZINE DERIVATIVES AND DRUGS CONTAINING THE SAME Kowa Co., Ltd. (JP) 2004-06-23 EP disclosed
US-20040002497-A1 Water-soluble phenylpyridazine compounds and compositions containing the same KOWA CO., LTD. (JP) 2004-01-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180195039-A1 APPLICATION OF ETHYL P-METHOXYCINNAMATE AND DERIVATIVES THEREOF IN MAINTAINING SELF-RENEWAL AND PLURIPOTENCY OF STEM CELLS XPA, MEP1A, EED L3MBTL1 814/4885MAPT 4688/4885CA12 4873/4885
US-20060142292-A1 4-(4-tert-butoxycarbonyl-1-piperazinyl)methyl-6-(3-fluoro-4-methylphenyl)-2-isobutyl-2H-pyridazin-3-one;inhibiting interleukin-1 beta, high water solubility and oral absorbability; treating immune system diseases, inflammatory diseases, and ischemic diseases IL1B, IL1A, IL1R1 L3MBTL1 3118/4885MAPT 2720/4885CA12 4744/4885
US-10723998-B2 Application of ethyl p-methoxycinnamate and derivatives thereof in maintaining self-renewal and pluripotency of stem cells XPA, MEP1A, EED L3MBTL1 814/4885MAPT 4688/4885CA12 4873/4885
US-20040002497-A1 Water-soluble phenylpyridazine compounds and compositions containing the same IL1A, IL1B, IL1R1 L3MBTL1 4349/4885MAPT 4306/4885CA12 4412/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.